Skip to navigation Skip to content

News

Share

Mouse Study Shows Possible Benefits of Targeting Immune Messenger IL-17A in MS

February 7, 2020

The immune messenger protein IL-17A has long been known to be a major player in the immune attacks that underlie MS. Researchers at Trinity College Dublin are now reporting that – in studies in mice with MS-like disease -- IL-17A appears to act by priming other immune system components, and not by triggering inflammation itself. Eliminating IL-17A from mice or treating them with inhibitors of IL-17A enabled the mice to resist getting MS-like disease. Antibodies targeting this immune protein are in development, and one has been approved to treat another immune-mediated disease – plaque psoriasis. These studies can serve to inform similar future efforts in MS.

Read more from Trinity College

Read a summary of the paper in Immunity

About Multiple Sclerosis

Multiple sclerosis is an unpredictable, often disabling disease of the central nervous system that disrupts the flow of information within the brain, and between the brain and body. Symptoms range from numbness and tingling to blindness and paralysis. The progress, severity and specific symptoms of MS in any one person cannot yet be predicted, but advances in research and treatment are leading to better understanding and moving us closer to a world free of MS. Most people with MS are diagnosed between the ages of 20 and 50, with at least two to three times more women than men being diagnosed with the disease. MS affects more than 2.3 million people worldwide.

Share


© 2020 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization and our Identification Number (EIN) is 13-5661935.